Veracyte, Inc. (NASDAQ:VCYT) Stock Has Consensus Price Target of $55.78 According to Brokerages

Veracyte, Inc. (NASDAQ:VCYT) has received a consensus rating of “Hold” from the twelve ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $51.40.

A number of analysts have recently weighed in on the stock. UBS Group increased their target price on shares of Veracyte from $52.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Piper Sandler decreased their price objective on shares of Veracyte from $66.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Wall Street Zen cut shares of Veracyte from a “buy” rating to a “hold” rating in a research report on Saturday. Leerink Partners lowered shares of Veracyte from an “outperform” rating to a “market perform” rating and cut their target price for the company from $55.00 to $35.00 in a research note on Thursday. Finally, Canaccord Genuity Group reduced their price target on Veracyte from $60.00 to $50.00 and set a “hold” rating on the stock in a research note on Monday, August 3rd.

Veracyte Price Performance

Shares of VCYT stock opened at $24.16 on Thursday. The business has a 50-day moving average of $44.07 and a 200 day moving average of $42.87. Veracyte has a 1-year low of $21.91 and a 1-year high of $60.91. The stock has a market capitalization of $1.94 billion, a PE ratio of 15.59 and a beta of 1.98.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.10. The business had revenue of $151.75 million for the quarter, compared to analysts’ expectations of $147.13 million. Veracyte had a return on equity of 8.99% and a net margin of 21.80%. The business’s quarterly revenue was up 15.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.51 EPS. Analysts anticipate that Veracyte will post 1.32 EPS for the current year.

Insider Transactions at Veracyte

In related news, Director Muna Bhanji sold 1,864 shares of the stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $43.70, for a total value of $81,456.80. Following the completion of the transaction, the director directly owned 40,854 shares in the company, valued at $1,785,319.80. This trade represents a 4.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jens Holstein sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $50.00, for a total transaction of $375,000.00. Following the transaction, the director directly owned 27,471 shares of the company’s stock, valued at $1,373,550. This represents a 21.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 62,609 shares of company stock worth $2,858,904. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Veracyte

Hedge funds have recently added to or reduced their stakes in the stock. William Blair Investment Management LLC boosted its stake in shares of Veracyte by 89.2% in the 3rd quarter. William Blair Investment Management LLC now owns 2,709,212 shares of the biotechnology company’s stock worth $124,732,000 after buying an additional 1,277,616 shares during the last quarter. Allworth Financial LP increased its position in Veracyte by 81.4% during the third quarter. Allworth Financial LP now owns 1,533 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 688 shares during the last quarter. Russell Investments Group Ltd. increased its position in Veracyte by 7.8% during the third quarter. Russell Investments Group Ltd. now owns 97,813 shares of the biotechnology company’s stock valued at $4,503,000 after acquiring an additional 7,088 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new position in Veracyte in the third quarter valued at about $34,000. Finally, Fifth Third Bancorp lifted its holdings in Veracyte by 7.5% in the third quarter. Fifth Third Bancorp now owns 55,232 shares of the biotechnology company’s stock valued at $2,543,000 after acquiring an additional 3,831 shares during the period.

Key Headlines Impacting Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Veracyte reported Q3 adjusted EPS of $0.51, ahead of estimates, and revenue of $151.75 million, up 15.1% year over year and above consensus. Veracyte tops Q3 earnings and revenue estimates
• Positive Sentiment: The company authorized a share buyback plan, which could provide some support for the stock, though the provided report does not specify its size or timing. Veracyte authorizes a buyback plan
• Negative Sentiment: The main concern is Veracyte’s reduced 2026 revenue outlook, tied to slower-than-expected growth in Decipher Prostate volumes. Management also cited increased investment in breast and bladder cancer tests, potentially weighing on near-term margins and growth. Q3 call highlights slower growth and added investment
• Negative Sentiment: Analyst sentiment weakened after the outlook cut: Leerink Partners downgraded VCYT to Market Perform from Outperform and lowered its price target to $35 from $55. Needham also reduced its target, to $46 from $69, while retaining a Buy rating. Veracyte downgraded after guidance cut
• Negative Sentiment: Several law firms announced investigations into potential securities claims following the company’s disclosures and sharp share-price decline. These are investigations, not findings of wrongdoing, but may add uncertainty for investors. Shareholder investigation notice

About Veracyte

Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests are designed to provide additional molecular information from patient samples, often helping reduce uncertainty and support more personalized care.

The company’s portfolio includes Afirma tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests for breast cancer. Veracyte also develops and commercializes additional genomic assays intended for use across various cancer types and clinical settings.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte primarily serves the U.S.